Brainomix Wins Top Healthtech Awards for Transformative AI in Stroke and Lung Care

Oxford-based AI innovator Brainomix has earned two prestigious accolades, solidifying its position as a leader in health technology. The company was named "Healthtech Company of the Year" by HSBC Innovation Banking at the LSX European Lifestars Awards and received the title of "Most Transformative Healthtech Company of the Year" from OBN. Both awards highlight Brainomix's advancements in AI-driven imaging solutions that are reshaping healthcare delivery, particularly in stroke and lung fibrosis care. Over the past year, the company achieved significant milestones, including National Institute for Health and Care Excellence (NICE) endorsement and multiple FDA clearances, further driving its expansion into the U.S. market.

Brainomix’s AI-powered platform, Brainomix 360 Stroke, has proven transformative in stroke care by significantly increasing the number of patients eligible for mechanical thrombectomy—a life-saving procedure for severe stroke cases. The technology has been rolled out nationwide in Hungary and Wales, leading to a 50% increase in thrombectomy rates in Hungary and a 44% rise in Wales. Dr. Shakeel Ahmad, National Clinical Lead for Stroke in Wales, described the platform as a "game-changer" that provides vital insights from routine brain scans, allowing for faster, more accurate treatment decisions.

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, expressed pride in the company’s achievements. “These awardrecogniseze the global impact of our AI solutions on patient care. We remain dedicated to expanding access to faster diagnoses and life-saving treatments,” he said. With Brainomix 360 Stroke now operational across 28 sites in Hungary, Professor István Szikora from Budapest's National Institute of Mental Health noted the substantial improvement in stroke care efficiencyemphasisingng its vital role in reducing disability and enhancing patient outcomes.